Lifirafenib + Mirdametinib for Cancer

Recruiting in Palo Alto (17 mi)

+5 other locations

Age: 18+

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Phase 1

Waitlist Available

Sponsor: BeiGene

Must not be taking: CYP3A inhibitors, Glucocorticoids

Disqualifiers: CNS metastasis, Glaucoma, HIV, others

No Placebo Group

Trial Summary

What is the purpose of this trial?

This trial is testing a combination of two experimental drugs, lifirafenib and mirdametinib, in people with tumors. The goal is to see if these drugs can work together to stop or slow down tumor growth by blocking signals that cancer cells need to grow.

Will I have to stop taking my current medications?

The trial requires that you stop taking certain medications, including chemotherapy, immunotherapy, biologic therapy, hormonal, or molecular targeted therapy within 2 weeks before starting the study. You also cannot take certain other medications like strong CYP3A inhibitors or systemic glucocorticoid therapy within 2 weeks before the trial.

What data supports the effectiveness of the drug Lifirafenib in treating cancer?

Research shows that Lifirafenib, a drug targeting specific proteins involved in cancer growth, was found to be safe, tolerable, and effective in treating patients with various solid tumors that have certain genetic mutations. ^{1 2 3 4 5}

What makes the drug combination of Lifirafenib and Mirdametinib unique for cancer treatment?

The combination of Lifirafenib and Mirdametinib is unique because it targets specific mutations in cancer cells, such as B-RAF and K-RAS/N-RAS mutations, which are not addressed by many standard treatments. Lifirafenib inhibits multiple RAF family kinases and EGFR, while Mirdametinib is a MEK inhibitor, making this combination potentially effective for tumors with these genetic mutations. ^{1 6 7 8 9}

Research Team

Katie Wood

Principal Investigator

BeiGene

Eligibility Criteria

Adults with advanced solid tumors who can provide a tumor sample and consent, have a life expectancy over 12 weeks, measurable disease per RECIST 1.1, good performance status (ECOG ≤1), adequate organ function, and agree to use contraception can join. Exclusions include CNS metastasis, certain heart conditions, abnormal QT interval on ECG, active liver disease or infections like HIV/Hepatitis B/C.

Inclusion Criteria

My cancer has spread, cannot be surgically removed, and is getting worse.

I can carry out all my self-care but cannot do heavy physical work.

My organs are working well and I haven't had a transfusion in the last 2 weeks.

Exclusion Criteria

I haven't had severe bleeding in the last 28 days.

My heart's pumping ability is below normal.

Underlying medical conditions in investigator's opinion to be unfavorable to be a part of the study

Treatment Details

Interventions

• Lifirafenib (Kinase Inhibitor)
• Mirdametinib (Kinase Inhibitor)

Trial Overview The trial is testing the combination of two drugs: Lifirafenib (BGB-283) and Mirdametinib (PD-0325901) in adults with various types of advanced solid tumors. It's designed to assess safety and how the body processes these drugs.

Participant Groups

Group I: Part B: Expansion Experimental Treatment 2 Interventions

Approximately 20 participants with NRAS mutated solid tumors will be enrolled

Group II: Part A: Dose Escalation/Dose finding Dose Level Cohorts ranging in dose levels and dose regimens. Experimental Treatment 2 Interventions

Combination doses of, Mirdametinib at once a day and lifirafenib at once a day And Mirdametinib at twice a day and lifirafenib at once a day

Who Is Running the Clinical Trial?

BeiGene

Lead Sponsor

Trials

216

Recruited

32,500+

SpringWorks Therapeutics, Inc.

Industry Sponsor

Trials

14

Recruited

900+

Findings from Research

Lifirafenib, a new drug targeting B-RAF and other kinases, was found to be safe and tolerable at a maximum dose of 40 mg/day, with common side effects including hypertension and fatigue.

The drug showed promising antitumor activity in patients with B-RAF mutations, achieving complete and partial responses in various solid tumors, while also demonstrating efficacy in some K-RAS-mutated cancers.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Phase I, Open-Label, Dose-Escalation/Dose-Expansion Study of Lifirafenib (BGB-283), an RAF Family Kinase Inhibitor, in Patients With Solid Tumors. Desai, J., Gan, H., Barrow, C., et al.[2021]

In a subgroup of 109 patients with EGFR-mutant NSCLC from the MARQUEE study, the combination of erlotinib and tivantinib significantly improved progression-free survival, with a median of 13.0 months compared to 7.5 months for erlotinib alone.

The combination therapy also showed a trend towards improved overall survival, with a median of 25.5 months for erlotinib plus tivantinib versus 20.3 months for erlotinib plus placebo, although the results were not statistically significant.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Tivantinib in Combination with Erlotinib versus Erlotinib Alone for EGFR-Mutant NSCLC: An Exploratory Analysis of the Phase 3 MARQUEE Study. Scagliotti, GV., Shuster, D., Orlov, S., et al.[2019]

The combination of tivantinib and sorafenib was found to be safe and tolerable in 87 patients with advanced solid tumors, with the most common side effects being rash, diarrhea, and anorexia, but no unexpected toxicities were reported.

Preliminary results showed a 12% overall response rate, with higher efficacy in specific cancers: 26% in melanoma, 15% in renal cell carcinoma, and 10% in hepatocellular carcinoma, indicating potential therapeutic benefits for these tumor types.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Phase 1 trial of tivantinib in combination with sorafenib in adult patients with advanced solid tumors. Puzanov, I., Sosman, J., Santoro, A., et al.[2021]

In a phase I trial, BGB-283 was shown to be safe and well-tolerated in patients with solid tumors that have mutations in BRAF, KRAS, and NRAS.

The trial demonstrated that BGB-283 is effective in treating these tumors, indicating its potential as a targeted therapy for specific genetic mutations.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

BGB-283 Deemed Effective in Phase I Study. [2018]

This phase I/II clinical trial is investigating the safety and efficacy of a combination treatment involving selumetinib, tremelimumab, and durvalumab in 40 patients with previously treated, unresectable non-small-cell lung cancer (NSCLC).

The study aims to determine the maximum tolerated dose and progression-free survival, while also exploring biomarkers of response and resistance, which could help tailor future treatments for NSCLC patients.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Phase I/II Trial of Immunotherapy With Durvalumab and Tremelimumab With Continuous or Intermittent MEK Inhibitor Selumetinib in NSCLC: Early Trial Report. Gaudreau, PO., Lee, JJ., Heymach, JV., et al.[2021]

The maximum tolerated doses (MTDs) for the combination of pembrolizumab and trametinib were established, with concurrent dosing showing a lower objective response rate (0%) compared to intermittent dosing (27%).

While the combination treatment had manageable safety profiles, with 31% of patients experiencing grade 3/4 treatment-related adverse events in the concurrent group, the overall antitumor activity was limited, suggesting that this combination may not be highly effective for solid tumors and BRAF wild-type melanoma.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

KEYNOTE-022: Pembrolizumab with trametinib in patients with BRAF wild-type melanoma or advanced solid tumours irrespective of BRAF mutation. Maio, M., Carlino, MS., Joshua, AM., et al.[2022]

References

1. United States pubmed.ncbi.nlm.nih.gov

Phase I, Open-Label, Dose-Escalation/Dose-Expansion Study of Lifirafenib (BGB-283), an RAF Family Kinase Inhibitor, in Patients With Solid Tumors. [2021]

2. United States pubmed.ncbi.nlm.nih.gov

Tivantinib in Combination with Erlotinib versus Erlotinib Alone for EGFR-Mutant NSCLC: An Exploratory Analysis of the Phase 3 MARQUEE Study. [2019]

3. United States pubmed.ncbi.nlm.nih.gov

Phase 1 trial of tivantinib in combination with sorafenib in adult patients with advanced solid tumors. [2021]

4. United States pubmed.ncbi.nlm.nih.gov

Nephrotoxicity of the BRAF Inhibitors Vemurafenib and Dabrafenib. [2022]

5. United States pubmed.ncbi.nlm.nih.gov

BGB-283 Deemed Effective in Phase I Study. [2018]

6. United States pubmed.ncbi.nlm.nih.gov

Combined BRAF and MEK Inhibition With Dabrafenib and Trametinib in BRAF V600-Mutant Colorectal Cancer. [2022]

7. United States pubmed.ncbi.nlm.nih.gov

Phase I/II Trial of Immunotherapy With Durvalumab and Tremelimumab With Continuous or Intermittent MEK Inhibitor Selumetinib in NSCLC: Early Trial Report. [2021]

8. United States pubmed.ncbi.nlm.nih.gov

Phase I trial of sorafenib in combination with gefitinib in patients with refractory or recurrent non-small cell lung cancer. [2018]

9. England pubmed.ncbi.nlm.nih.gov

KEYNOTE-022: Pembrolizumab with trametinib in patients with BRAF wild-type melanoma or advanced solid tumours irrespective of BRAF mutation. [2022]